

## HR 2869

### Increasing Access to Biosimilars Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 28, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Apr 29, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/2869>

## Sponsor

**Name:** Rep. Cárdenas, Tony [D-CA-29]

**Party:** Democratic • **State:** CA • **Chamber:** House

## Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Craig, Angie [D-MN-2]	D · MN		Apr 28, 2021
Rep. Blunt Rochester, Lisa [D-DE-At Large]	D · DE		May 11, 2021

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 29, 2021
Ways and Means Committee	House	Referred to	Apr 28, 2021

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 S 1427	Related bill	Apr 28, 2021: Read twice and referred to the Committee on Finance.

## Summary (as of Apr 28, 2021)

### Increasing Access to Biosimilars Act of 2021

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

## Actions Timeline

---

- **Apr 29, 2021:** Referred to the Subcommittee on Health.
- **Apr 28, 2021:** Introduced in House
- **Apr 28, 2021:** Referred to the Subcommittee on Health.
- **Apr 28, 2021:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.